589 related articles for article (PubMed ID: 25528466)
1. A Bayesian prediction model between a biomarker and the clinical endpoint for dichotomous variables.
Jiang Z; Song Y; Shou Q; Xia J; Wang W
Trials; 2014 Dec; 15():500. PubMed ID: 25528466
[TBL] [Abstract][Full Text] [Related]
2. Bayesian approach to noninferiority trials for proportions.
Gamalo MA; Wu R; Tiwari RC
J Biopharm Stat; 2011 Sep; 21(5):902-19. PubMed ID: 21830922
[TBL] [Abstract][Full Text] [Related]
3. A hybrid Bayesian adaptive design for dose response trials.
Chang M; Chow SC
J Biopharm Stat; 2005; 15(4):677-91. PubMed ID: 16022172
[TBL] [Abstract][Full Text] [Related]
4. An analytical approach to assess the predictive value of biomarkers in Phase II decision making.
Nikolakopoulos S; van der Wal WM; Roes KC
J Biopharm Stat; 2013; 23(5):1106-23. PubMed ID: 23957519
[TBL] [Abstract][Full Text] [Related]
5. Simulation optimization for Bayesian multi-arm multi-stage clinical trial with binary endpoints.
Yu Z; Ramakrishnan V; Meinzer C
J Biopharm Stat; 2019; 29(2):306-317. PubMed ID: 30763151
[TBL] [Abstract][Full Text] [Related]
6. A Bayesian estimate of the concordance correlation coefficient with skewed data.
Feng D; Baumgartner R; Svetnik V
Pharm Stat; 2015; 14(4):350-8. PubMed ID: 26033433
[TBL] [Abstract][Full Text] [Related]
7. Bayesian adjusted R2 for the meta-analytic evaluation of surrogate time-to-event endpoints in clinical trials.
Renfro LA; Shi Q; Sargent DJ; Carlin BP
Stat Med; 2012 Apr; 31(8):743-61. PubMed ID: 22161275
[TBL] [Abstract][Full Text] [Related]
8. Robust meta-analytic-predictive priors in clinical trials with historical control information.
Schmidli H; Gsteiger S; Roychoudhury S; O'Hagan A; Spiegelhalter D; Neuenschwander B
Biometrics; 2014 Dec; 70(4):1023-32. PubMed ID: 25355546
[TBL] [Abstract][Full Text] [Related]
9. Predictive probability of success using surrogate endpoints.
Saint-Hilary G; Barboux V; Pannaux M; Gasparini M; Robert V; Mastrantonio G
Stat Med; 2019 May; 38(10):1753-1774. PubMed ID: 30548627
[TBL] [Abstract][Full Text] [Related]
10. Bayesian model selection techniques as decision support for shaping a statistical analysis plan of a clinical trial: an example from a vertigo phase III study with longitudinal count data as primary endpoint.
Adrion C; Mansmann U
BMC Med Res Methodol; 2012 Sep; 12():137. PubMed ID: 22962944
[TBL] [Abstract][Full Text] [Related]
11. Monitoring event times in early phase clinical trials: some practical issues.
Thall PF; Wooten LH; Tannir NM
Clin Trials; 2005; 2(6):467-78. PubMed ID: 16422307
[TBL] [Abstract][Full Text] [Related]
12. A Bayesian meta-analytic approach for safety signal detection in randomized clinical trials.
Odani M; Fukimbara S; Sato T
Clin Trials; 2017 Apr; 14(2):192-200. PubMed ID: 28059578
[TBL] [Abstract][Full Text] [Related]
13. Bayesian design and analysis of composite endpoints in clinical trials with multiple dependent binary outcomes.
Zaslavsky BG
Pharm Stat; 2013; 12(4):207-12. PubMed ID: 23625660
[TBL] [Abstract][Full Text] [Related]
14. Evidence synthesis from aggregate recurrent event data for clinical trial design and analysis.
Holzhauer B; Wang C; Schmidli H
Stat Med; 2018 Mar; 37(6):867-882. PubMed ID: 29152777
[TBL] [Abstract][Full Text] [Related]
15. A Bayesian predictive sample size selection design for single-arm exploratory clinical trials.
Teramukai S; Daimon T; Zohar S
Stat Med; 2012 Dec; 31(30):4243-54. PubMed ID: 22807115
[TBL] [Abstract][Full Text] [Related]
16. Bayesian approach for assessing noninferiority in a three-arm trial with binary endpoint.
Ghosh S; Tiwari RC; Ghosh S
Pharm Stat; 2018 Jul; 17(4):342-357. PubMed ID: 29473291
[TBL] [Abstract][Full Text] [Related]
17. Predicting analysis time in event-driven clinical trials with event-reporting lag.
Wang J; Ke C; Jiang Q; Zhang C; Snapinn S
Stat Med; 2012 Apr; 31(9):801-11. PubMed ID: 22344853
[TBL] [Abstract][Full Text] [Related]
18. Exploring the relationship between the causal-inference and meta-analytic paradigms for the evaluation of surrogate endpoints.
Van der Elst W; Molenberghs G; Alonso A
Stat Med; 2016 Apr; 35(8):1281-98. PubMed ID: 26612787
[TBL] [Abstract][Full Text] [Related]
19. A Bayesian basket trial design using a calibrated Bayesian hierarchical model.
Chu Y; Yuan Y
Clin Trials; 2018 Apr; 15(2):149-158. PubMed ID: 29499621
[TBL] [Abstract][Full Text] [Related]
20. Milestone prediction for time-to-event endpoint monitoring in clinical trials.
Ou FS; Heller M; Shi Q
Pharm Stat; 2019 Jul; 18(4):433-446. PubMed ID: 30806485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
